CROS NT Ltd Announces Acquisition of MDSL International Ltd.
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.
Andrew MacGarvey, CEO and President of CROS NT, said, "I am delighted to expand the UK operation through this acquisition. We are adding a highly experienced team to the business and further diversifying our customer base - both important objectives of the CROS NT Group. We will move our UK Headquarters to Maidenhead, giving us a great location in terms of on-going recruitment and access to our customers given its proximity to London. Coming shortly after our acquisition of Stat-Tech Services in the USA, this deal demonstrates our commitment to place expertise close to our customers and to grow to meet the increasing demand for our services."
Edmund Otun, the founder of MDSL International, said, "I am pleased to have concluded the deal with CROS NT. Being part of a larger entity allows us to provide additional resources to our existing clients - something they have been asking for. CROS NT has a very strong management team, with great experience in the CRO business. I will remain with the company providing consultancy for emerging companies seeking advice on getting their products to market or securing licencing deals."
Jo Marshall, MDSL International Managing Director, who will become the UK Country Manager for CROS NT Ltd added, "I am excited by this opportunity and looking forward to working with the CROS NT team. In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several Electronic Data Capture (EDC) platforms, a Clinical Trial Management System (CTMS), and electronic Patient Recorded Outcomes (ePRO) solutions."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
